Company profile
NOVO NORDISK A S
NYSE:NVOBiotechnology: Pharmaceutical Preparations
Drug pipeline (17)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| CONCIZUMAB | approved | — | 9 | approved |
| GLUCAGON HYDROCHLORIDE | approved | — | 0 | — |
| INSULIN ASPART | approved | — | 109 | approved |
| INSULIN DEGLUDEC | approved | — | 114 | approved |
| INSULIN DETEMIR | approved | — | 64 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (1029)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02501161 | phase3 | completed | 2016-01-31 | 2018-10-03 | Novo Nordisk A/S | A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus |
| NCT01713530 | phase3 | completed | 2013-02-21 | 2014-01-09 | Novo Nordisk A/S | A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin |
| NCT02906917 | phase3 | completed | 2016-09-20 | 2017-08-31 | Novo Nordisk A/S | A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification |
| NCT02443155 | phase2 | completed | 2015-11-10 | 2018-08-31 | Novo Nordisk A/S | A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function |
| NCT04575181 | phase1 | completed | 2020-10-21 | 2021-12-10 | Novo Nordisk A/S | A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine |
FDA applications (36)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| ANDA 040312 | ANDA | NOVO NORDISK INC | ||||
Loading… | ||||||
| BLA 019938 | BLA | Novo Nordisk Inc. | ||||
Loading… | ||||||
| BLA 019959 | BLA | Novo Nordisk Inc. | ||||
Loading… | ||||||
| BLA 019991 | BLA | Novo Nordisk Inc. | ||||
Loading… | ||||||
| BLA 020986 | BLA | Novo Nordisk Inc. | ||||
Loading… | ||||||